Abstract

LUQUE, M. et al. Retrospective study of patients diagnosed of advanced stage non-small cell lung cancer treated by the combination of gemcitabine and vinorelbine: valuation of the therapeutic efficacy and prognostic factors. Oncología (Barc.) [online]. 2007, vol.30, n.2, pp.32-43. ISSN 0378-4835.

INTRODUCTION: Gemcitabine (G), vinorelbine (V) and their combination (GV) have shown to be useful in patients with non-small cell lung cancer (NSCLC). The purpose of this study is to confirm the activity of GV administration and to identify prognostic factors related with the clinical outcome. METHODS: A retrospective analysis was carried out in relation to 144 patients with NSCL treated between October 1996 and April 2005 with G (1000-1250 mg/m²) + V (25-30 mg/m²) both administered on days 1 and 8 every three weeks. RESULTS: Treatment was well tolerated, grade 3-4 neutropenia being registered as the worse toxic effect in 18% cases, including 7% of neutropenic fever. The objective response rate was 36.8% (95% CI: 28.9-44.7) and the median progression free survival and overall survival rates were 21 (18-25) and 33 (26-40) weeks respectively. In multivariate analysis only the histology of adenocarcinoma (HR 3; p<0.001), less than two metastatic sites (HR 1.7; p<0.02) and Karnofsky index (KI) above 70% (HR 1.5; p<0.02) showed a significant association with longer survival. CONCLUSION: The GV combination therapy is well tolerated and active in patients with advanced NSCLC. The histology of adenocarcinoma, less than two metastatic sites and KI above 70% were identified as independent variables related with longer survival.

Keywords : Non-small cell lung cancer; Gemcitabine; Vinorelbine; Prognostic factors.

        · abstract in Spanish     · text in Spanish     · Spanish ( pdf )